Are outcomes of locally advanced cervical cancer associated with prebrachytherapy hemoglobin values and transfusion practice? An observational study comparing two large academic centres with divergent clinical guidelines

被引:0
|
作者
Dear, Taylor [1 ]
Chiu, Jodi [2 ]
Meirovich, Harley [3 ]
Malkin, Amie [3 ,4 ]
Amjad, Razan [5 ,6 ]
D'Souza, David [6 ]
Callum, Jeannie [7 ]
Leung, Eric [8 ]
Kelly, Kate [2 ]
Lazo-Langner, Alejandro [2 ]
Solh, Ziad [2 ,9 ]
机构
[1] Univ Toronto, Dept Med, Div Hematol, Toronto, ON, Canada
[2] Western Univ, Dept Med, Div Hematol, London, ON, Canada
[3] Univ Toronto, QUEST Res Program, Toronto, ON, Canada
[4] Sunnybrook Hlth Sci Ctr, Precis Diagnost & Therapeut Program, Toronto, ON, Canada
[5] King Abdulaziz Univ, Dept Radiat Oncol, Rabigh, Saudi Arabia
[6] Western Univ, Dept Oncol, Div Radiat Oncol, London, ON, Canada
[7] Queens Univ, Dept Pathol & Mol Med, Kingston & Sunnybrook Res Inst, Toronto, ON, Canada
[8] Sunnybrook Hlth Sci Ctr, Div Radiat Oncol, Dept Oncol, Toronto, ON, Canada
[9] Western Univ, Dept Pathol & Lab Med, Transfus Med, London, ON, Canada
关键词
Cervical cancer brachytherapy; Transfusion; Hemoglobin; Anemia; Radiation; BLOOD-CELL TRANSFUSION; NECK-CANCER; RADIOTHERAPY; ERYTHROPOIETIN; REQUIREMENTS; THRESHOLDS; STRATEGIES; RADIATION; MORTALITY; ANEMIA;
D O I
10.1016/j.brachy.2024.07.006
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
BACKGROUND AND PURPOSE: Anemia is common in locally advanced cervical cancer. Clinical practice varies greatly for management of anemia during brachytherapy, with some centres providing red cell transfusion to increase hemoglobin levels above 100 g/L. MATERIALS AND METHODS: This is a retrospective observational cohort study of adult patients with cervical cancer treated with brachytherapy at two academic hospitals. One hospital (H1) uses a liberal transfusion strategy with hemoglobin threshold of 100 g/L during brachytherapy and the other uses a restrictive target of 70 g/L (H2). RESULTS: Overall, 336 patients met inclusion criteria (H1: 150 patients, H2: 186 patients). 11 patients were excluded (2 at H1, 9 at H2). Demographics at both sites were comparable, except for cancer stage and smoking history. External beam radiation and chemotherapy provided was similar. Hemoglobin values were compared at baseline (within 4 weeks of oncology consult), and prior to the first and second brachytherapy treatments. In total, 101red blood cell (RBC) units were transfused to patients at H1 and 19 units to patients at H2. Patients were followed for a median of 37.0 months (0.6-80.5) at H1, and 33.3 months (1.6-82.0) at H2. There was no significant difference in progression-free or overall survival. Multivariable logistic regression analysis showed that FIGO stage was a predictor for both overall survival and cancer progression. Age, tumor size, chemotherapy, and hemoglobin levels were not predictors of disease progression or mortality. CONCLUSIONS: The practice of liberal transfusion should be re-evaluated in the absence of robust data to support its use. Crown Copyright (c) 2024 Published by Elsevier Inc. on behalf of American Brachytherapy Society. All rights are reserved, including those for text and data mining, AI training, and similar technologies.
引用
收藏
页码:660 / 667
页数:8
相关论文
共 2 条
  • [1] Split-dose cisplatin plus gemcitabine use and associated clinical outcomes in the first-line (1L) treatment of locally advanced or metastatic urothelial cancer (la/mUC): Results of a retrospective observational study in Germany (CONVINCE)
    Schlack, K.
    Kubin, T.
    Ruhnke, M.
    Schulte, C.
    Machtens, S.
    Eisen, A.
    Osowski, U.
    Guenther, S.
    Kearney, M.
    Lipp, R.
    Schmitz, S.
    ANNALS OF ONCOLOGY, 2023, 34 : S1216 - S1216
  • [2] Split-dose cisplatin (C) plus gemcitabine (G) use and associated clinical outcomes in the first-line (1L) treatment (tx) of locally advanced or metastatic urothelial cancer (la/mUC): results of a retrospective observational study in Germany (CONVINCE)
    Schlack, Katrin
    Kubin, Thomas W.
    Ruhnke, Markus
    Schulte, Clemens
    Machtens, Stefan
    Eisen, Anna
    Osowski, Ulrike
    Guenther, Silke
    Kearney, Mairead
    Lipp, Rainer
    Schmitz, Stephan
    ONCOLOGY RESEARCH AND TREATMENT, 2024, 47 : 83 - 83